The Department of Bioengineering at the Phil and Penny Knight Campus for Accelerating Scientific Impact will host a two-day Next Generation Biomaterials workshop on May 13-14, 2024. Developed in collaboration with the UO’s Department of Chemistry and Biochemistry and the Materials Science Institute, the symposium will welcome 48 preeminent scholars, including thought leaders from industry, academics, national labs, and scientific publishing. This workshop is funded through a new collaboration between the National Science Foundation's Division of Materials Research (DMR) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB).

The Department of Bioengineering at the Phil and Penny Knight Campus for Accelerating Scientific Impact will host a two-day Next Generation Biomaterials workshop on May 13-14, 2024. Developed in collaboration with the UO’s Department of Chemistry and Biochemistry and the Materials Science Institute, the symposium will welcome 48 preeminent scholars, including thought leaders from industry, academics, national labs, and scientific publishing. This workshop is funded through a new collaboration between the National Science Foundation's Division of Materials Research (DMR) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB).

About the talk:

About Sean McClain:

Sean McClain is the Founder and CEO of Absci, a leading generative AI Drug Creation company with a mission to create better biologics for patients, faster.  Sean embodies entrepreneurial spirit, having built Absci from basement lab to a publicly traded company and continuing to strive towards his vision to create therapeutics at the click of a button. Under his leadership, Absci scaled to over 200 employees, raised over $530M in capital, established a growing number of industry-leading partnerships, developed an internal portfolio of AI discovered drug assets, and built an Integrated Drug Creation Platform that merges bleeding-edge generative AI models with proprietary high-throughput wet-lab data. 

Sean is a graduate of the University of Arizona and has been the recipient of numerous recognitions for his entrepreneurship and innovation. He serves as a board member for the Oregon Translational Research and Development Institute, and Life Science Washington.